Clinical Trials Logo

Clinical Trial Summary

Menstrual staphylococcal toxic shock is a rare but severe disease, requiring intensive care in over 80% of cases. Menstrual staphylococcal toxic shock develops during the peri-menstrual period, in healthy young women colonized by a vaginal strain of Staphylococcus aureus secreting the Toxic shock syndrome toxin 1 (TSST-1) and not immune to it, in a favorable environment, i.e. wearing intravaginal menstrual protection (tampon, menstrual cup). The rarity of the syndrome, its polymorphous clinical presentation and the absence of a totally specific biological examination make menstrual staphylococcal toxic shock a difficult pathology to diagnose. The reference clinical criteria correspond to the advanced picture of multivisceral failure, making it possible to classify cases a posteriori, but contribute to diagnostic delay and lack sensitivity. Patient accounts suggest the presence of symptoms in the days preceding the development of toxic shock, and also during previous menstrual cycles. The identification of prodromal symptoms could enable earlier management of menstrual staphylococcal toxic shock by removal of intra-vaginal sanitary protection, the main risk factor, before the disease becomes permanently established and requires intensive care.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT06124599
Study type Observational
Source Hospices Civils de Lyon
Contact Gerard LINA, MD
Phone 04 72 07 16 94
Email gerard.lina@chu-lyon.fr
Status Recruiting
Phase
Start date December 21, 2021
Completion date December 21, 2026

See also
  Status Clinical Trial Phase
Completed NCT00974935 - Phase I STEBVax in Healthy Adults Phase 1